ArticleFrontiers in public health2026
Digital transformation, green finance, and pharmaceutical affordability in China: a health economics perspective.
Article in Frontiers in public health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Drug accessibility is a core challenge facing global public health systems, with financing costs directly affecting drug prices through cost-plus pricing mechanisms. This study aims to examine how digital transformation influences pharmaceutical companies' financing costs by promoting green certification and green finance availability, and to explore the heterogeneous effects of essential drug enterprises and their public health significance. Methods: Based on 1,216 observations from 152 A-share listed pharmaceutical manufacturing companies in China from 2016-2023, this study employs fixed-effects panel data models to test the impact of digital transformation on financing costs, uses Bootstrap methods to test chain mediation effects, and controls for endogeneity through instrumental variable methods and propensity score matching-difference-in-differences approaches. Results: Digital transformation significantly increases the probability of enterprises obtaining green certification (β = 0.079, Discussion: Digital transformation significantly reduces pharmaceutical companies' financing costs through the chain mediation of green certification and green finance, with the effect being more pronounced for essential drug enterprises. The reduction in financing costs may create room for price adjustment. Under China's essential drug price regulation system, cost savings could potentially be transmitted to essential drug prices, which has theoretical implications for improving drug accessibility and promoting health equity. It is recommended to improve the green finance standard system, strengthen differentiated policy support for essential drug enterprises, and establish a linkage mechanism between financing costs and drug prices.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.